| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.16 | 0.008 |
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.4 | 0.009 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.2 | 0.01 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.22 | 0.01 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |